News
Biohit Group Financial Statement Release 2014
26.02.2015 09:30
Upcoming Events
10.03.
IDS (International Dental Show)
Cologne, German
16.04.
Silent Period (Interim report Q1-2015)
20.04.
Biohit Oyj’s Annual General Meeting 2015
Helsinki, Finland
Groundbreaking Diagnostics
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit’s mission is “Innovating for Health”.
Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki since 1999, Small cap/Healthcare.
Study Protocols
Biohit shares study protocols, i.e., descriptions of clinical studies designed for validation of Biohit Oyj’s diagnostic tests as well as for evaluation of therapeutic efficacy of Biohit’s Acetium capsule and lozenge products in current and novel clinical indications.
Innovations
Biohit's products and services are safe, ethical and costefficient innovations for diagnosing and preventing gastrointestinal diseases and the associated risks.
- About Us
- Scientific
- GastroPanel Research
- Prevalence of H. pylori Infection and Atrophic Gastritis Among Symptomatic and Dyspeptic Adults in Kazakhstan
- A simple blood test reveals whether the stomach is healthy or not
- Finnish FIT test for more efficient screening of colorectal cancer
- Acetium Reasearch
- Reseach information on Acetium
- Acetaldehyde, Group I human carcinogen
- State of the art GastroPanel and Acetium innovations for the unmet need
- Scientific Committee on Consumer Safety - Opinion on Acetaldehyde
- GastroPanel indications
- Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers
- Literature
- Study Protocols
- Investors
- Laboratory Services
- Products
- Partnering
- Contact Us